The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
The market for weight loss drugs—a $100 billion prize by the 2030s—is not merely growing; it is demanding ruthless efficiency.
By Bram de Vries ·
novo nordisk — Lorien Times
Eli Lilly’s Mounjaro revenue is just modern-day oil money extraction
The quarterly earnings report is supposed to tell us about market health; instead, it’s another flashing neon sign of where America's care infrastructure has failed—and who gets rich from it.
By Josie Calloway ·
Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said
The feverish adoration for any single pharmaceutical breakthrough—be it a miracle weight-loss pill or a cardiovascular panacea—always carries an inherent, dangerous hubris.
By Elena Rossi ·
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
The market doesn’t care about science; it cares about momentum, and right now, Novo Nordisk is hemorrhaging both.
By Imani Sutton ·